Search
Spotlight
In-person and virtual events just for HCPs
In-person and virtual events just for HCPs
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
Pipeline Report
OncClub
All Oncology News
Pipeline Report
Media
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Insights
Medical World News
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
The Talk
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Giants of Cancer Care
PER Events
Scientific Interchanges
State of the Science Summit / IPC
Webinars
Partners
Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
Oncology Live®
Oncology Fellows
Supplements and Featured Publications
All Publications
CME/CE
Resources
Interactive Tools
Learning Modules
Sponsored
Interactive Tools
Learning Modules
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
In-person and virtual events just for HCPs
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Alan P. Skarbnik, MD, Novant Health Cancer Institute
home
Articles
Relapsed/Refractory CLL Treatment: Addressing Unmet Needs
February 8th 2021
Frontline CLL Treatment: Addressing Unmet Needs
January 8th 2021
Allogeneic Transplantation for CLL
January 8th 2021
Relapsed/Refractory CLL: Repeat Molecular Testing
January 8th 2021
Therapeutic Sequencing in Relapsed/Refractory CLL
January 8th 2021
CLL Patient Management During COVID-19 and Telehealth
January 8th 2021
CLL Treatment Approaches During COVID-19
January 8th 2021
Frontline CLL: Treatment Algorithms
January 8th 2021
Minimal Residual Disease in CLL
January 8th 2021
Frontline CLL Treatment With Fixed-Duration Regimens
January 8th 2021
Anti-BCL2/CD20 Combination Therapy for Frontline CLL
January 8th 2021
Anti-CD20/BTKi Therapy for Frontline CLL
January 8th 2021
BTK Monotherapy for Frontline CLL
January 8th 2021
Selecting Frontline Therapy to Treat CLL
January 8th 2021